

1 Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the  
2 treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study

3  
4 Hanlin Zhang<sup>1,2#</sup>, Yiming Zhao<sup>3#</sup>, Xiaoxiao Jiang<sup>1,2#</sup>, Yuying Zhao<sup>4#</sup>, Li Yang<sup>5#</sup>, Li Chen<sup>1,2#</sup>, Meng  
5 Dong<sup>1#</sup>, Zhe Luan<sup>6#</sup>, Chunlong Yan<sup>7</sup>, Jianwei Jiao<sup>8</sup>, Chaoyue Zhao<sup>9,10</sup>, Hongyue Li<sup>9,10</sup>, Wei Chen<sup>11</sup>,  
6 Cong Feng<sup>11</sup>, Le Tian<sup>12</sup>, Enqiang Qin<sup>13</sup>, Jinsong Mu<sup>14</sup>, Congyong Li<sup>15</sup>, Tianshu Zeng<sup>16\*</sup>, Shibo  
7 Feng<sup>17\*</sup>, Shufang Wang<sup>6\*</sup>, Xizhou Guan<sup>18\*</sup>, Tanshi Li<sup>11\*</sup>, Haotian Yu<sup>12\*</sup>, Aihua-Zheng<sup>9,10\*</sup>, Wanzhu  
8 Jin<sup>1\*</sup>, Gang Sun<sup>6\*</sup>

9  
10 Affiliations:

11 <sup>1</sup> Key Laboratory of Animal Ecology and Conservation Biology, Institute of Zoology, Chinese  
12 Academy of Sciences, Beijing100101, China

13 <sup>2</sup>University of Chinese Academy of Sciences, Beijing 100049, China

14 <sup>3</sup>Department of Gastroenterology and Hepatology, Hainan Hospital of PLA General Hospital,  
15 Sanya 572013, China

16 <sup>4</sup>Department of Cardiovascular Medicine, 980 Hospital of PLA Joint Logistics Support Forces,  
17 Shijiazhuang 050082, China

18 <sup>5</sup>Department of Endocrinology, Hankou Hospital of Wuhan City, Wuhan 430012, China

19 <sup>6</sup> Department of Gastroenterology and Hepatology, the first medical center, Chinese PLA General  
20 Hospital, Beijing 100853, China

21 <sup>7</sup> Agricultural College, Yanbian University, Yanji, 133002, China

22 <sup>8</sup>Savaid Medical School, University of the Chinese Academy of Sciences, Beijing, 100049, China

23 <sup>9</sup> State Key Laboratory of Integrated Management of Pest Insects and Rodents, Institute of Zoology,  
24 Chinese Academy of Sciences, Beijing 100101, China

25 <sup>10</sup> CAS Center for Excellence in Biotic Interactions, University of Chinese Academy of Sciences,  
26 Beijing 100049, China

27 <sup>11</sup>Emergency department, the first medical center, Chinese PLA General Hospital, Beijing 100853,  
28 China

29 <sup>12</sup>Department of health and logistics support, Hainan Hospital of PLA General Hospital, Sanya  
30 572013, China

31 <sup>13</sup>Department of Hepatology, the fifth medical center, Chinese PLA General Hospital, Beijing  
32 100853, China

33 <sup>14</sup>Intensive Care Unit, the fifth medical center, Chinese PLA General Hospital, Beijing 100853,  
34 China

35 <sup>15</sup>Department of Geriatric Gastroenterology, the sixth medical center, Chinese PLA General  
36 Hospital, Beijing 100048, China

37 <sup>16</sup>Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of  
38 Science and Technology, Wuhan 430022, China

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

39 <sup>17</sup>Department of Orthopaedics, Hankou Hospital of Wuhan City, Wuhan 430012, China

---

1 <sup>18</sup>Department of Respiratory Medicine, the first medical center, Chinese PLA General Hospital,  
2 Beijing 100853, China

3 **#These authors contributed equally to this work.**

4  
5 **\*Contact information for Correspondence:**

6 Tianshu Zeng M.D., Department of Endocrinology, Union Hospital, Tongji Medical College,  
7 Huazhong University of Science and Technology, Wuhan 430022, China; Hubei provincial Clinical  
8 Research Center for Diabetes and Metabolic Disorders, Wuhan 430022, China; tszeng@126.com;  
9 Shibo Feng M.D., Department of Orthopaedics, Hankou Hospital of Wuhan City, Wuhan 430012,  
10 China; 164837022@qq.com; Shufang Wang M.D., Department of Gastroenterology and  
11 Hepatology, the first medical center, Chinese PLA General Hospital, Beijing 100853, China;  
12 wangshufang@301hospital.com.cn; Xizhou Guan M.D., Department of Respiratory Medicine, the  
13 first medical center, Chinese PLA General Hospital, Beijing 100853, China; gxz301@126.com;  
14 Tanshi Li M.D., Emergency department, the first medical center, Chinese PLA General Hospital,  
15 Beijing 100853, China; lts301@163.com; Haotian Yu M.D., Department of health and logistics  
16 support, Hainan Hospital of PLA General Hospital, Sanya 572013, China; yht200725@163.com;  
17 Aihua-Zheng Ph.D., State Key Laboratory of Integrated Management of Pest Insects and Rodents,  
18 Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; CAS Center for  
19 Excellence in Biotic Interactions, University of Chinese Academy of Sciences, Beijing 100049,  
20 China; zhengaihua@ioz.ac.cn; Wanzhu Jin Ph.D., Key Laboratory of Animal Ecology and  
21 Conservation Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China;  
22 Savaid Medical School, University of the Chinese Academy of Sciences, Beijing, 100049, China;  
23 jinw@ioz.ac.cn; Gang Sun Ph.D. &M.D., Department of Gastroenterology and Hepatology, the first  
24 medical center, Chinese PLA General Hospital, Beijing 100853, China;  
25 sungang@301hospital.com.cn.

26

---

27

## 1 **Abstract**

### 2 **Background& Aims:**

3 The Coronavirus Disease 2019 (COVID-19) has become a global epidemic and has caused a  
4 lasting and huge loss of life security, economic development and social stability in more than 180  
5 countries around the world. Unfortunately, there is still no specific treatment for COVID-19 till now,  
6 therefore, at this point, all potential therapies need to be critically considered. LL-37 is one of the  
7 best-studied human antimicrobial peptide (AMPs) that has a broad-spectrum activity against  
8 bacteria and viruses. The use of living, genetically modified organisms (GMOs) is an effective  
9 approach for delivery of therapeutic proteins. The aim of this study was to determine the safety and  
10 efficacy of the Lactococcus lactis which has been genetically modified to produce the therapeutic  
11 human antimicrobial peptide LL-37 (herein after referred to cas001) in the patients of COVID-19.

### 12 **Methods:**

13 Firstly we constructed genetically modified food-grade probiotic, Lactococcus lactis, with sequence  
14 of seven tandem repeats of mature human LL-37 under control of the nisin-inducible nisA promoter  
15 to produce the cas001. A total of 20 healthy SD rats, half male and half female (There were five  
16 male and five female in the control group, the same in treatment group) were used to observe the  
17 acute toxic reaction and death after daily administration of cas001 for three weeks, which helps to  
18 provide necessary reference basis for clinical dose selection, verification of toxic reaction and  
19 possible target organs. According to the estimated clinical dosage of  $1 \times 10^8$ CFU /kg/day,  
20 considering the conversion of body surface area, the dose for rats should be multiplied by 6.17 to  $6$   
21  $\times 10^8$  CFU/kg/day. We administrated 100 times higher dose at  $6 \times 10^{10}$  CFU/ /kg/day to rats. In  
22 order to investigate the pharmacokinetics of cas001, male SD rats (body weight 250-300g,  $1 \times 10^{10}$   
23 /animal, n=3) were given oral administration of LL-37 bacteria powder. The concentration of LL-37  
24 in the blood before and after gavage was detected by ELISA kit (Hycult biotechnology Cat#  
25 HK321).

26  
27 Human clinical study was approved by Ethics committee of Chinese PLA General Hospital  
28 (S2020-074-04) and a total of 11 patients with mild symptoms were enrolled in Wuhan hankou  
29 hospital and Huoshenshan hospital. They were enrolled voluntarily and all patients signed informed  
30 consent. Among them, there were 5 males and 6 females, aged  $55 \pm 12$  (36-70) years old, and the  
31 duration from onset to medication enrollment was  $35 \pm 19$  (5-68) days. 6 patients were nucleic acid  
32 positive and 5 patients were nucleic acid negative when they were enrolled. All patients received  
33 the oral drug cas001 treatment according to requirement( $1 \times 10^9$  CFU/capsule, 3 capsules/time,  
34 three times a day for 3weeks), with an average follow-up time of  $33 \pm 15$  days (see table 1 for the  
35 results).

36  
37 **Findings:** Western blot analysis shows that reasonable amount of LL-37 were induced by different  
38 concentrations of nisin, which means we have successfully constructed cas001. In the pre-clinical  
39 safety evaluation test, after three weeks administration of cas001, no adverse effects were  
40 observed on the rat's body weight, food and water intake, hematological or serum biochemical  
41 parameters. The results showed that the LD<sub>50</sub> of cas001 was higher than that of the 100 times of  
42 the expected clinical dose of  $6 \times 10^{10}$  CFU/day. These results showed that cas001 could be safe in  
43 animal experiments. In addition, rat pharmacokinetics results showed that the serum concentration  
44 of LL-37 reached peak 2 hours after gavage of cas001 and returned to basal level 6 hours after  
45 gavage. During study period, the volunteers did not feel any discomfort while taking the cas001  
46 capsules, and two hours after oral administration, the concentration of LL-37 were increased in  
47 healthy volunteers.

48 cas001 shows definite effect in the improvement of gastrointestinal symptoms and is possible to  
49 have effects in improving the systemic symptoms and respiratory symptoms and may play a role in

1 the improvement of results of nucleic acid test and lung CT test. 11 patients enrolled showed good  
2 compliance, tolerance, subjective feeling and actively interacted with the doctors. None of the  
3 patients had any adverse reactions.

#### 4 **Conclusions**

5 Based on above observations, we conclude here that as an oral anti-viral agent, cas001 displayed  
6 good safety profiles. It is very hard to reach conclusion of clinical outcomes related to the cas001,  
7 although changes of several symptoms indicate encouraging findings.

#### 8 **Keyword:**

9 COVID-19, SARS-COV2, LL-37, Safety and Efficacy Clinical Study  
10 

---

11

## 1 Introduction

2  
3 On March 11, 2020, the director-general of World Health Organization (WHO) declared the severe  
4 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) situation as a pandemic<sup>1</sup>. By May 4, 2020,  
5 the number of cases of COVID-19 had increased exponentially. There have been more than 3  
6 million reported cases, 240 thousand death and the number of affected countries was more than  
7 200. Recent report has demonstrated that there is less than 80% sequence similarity between  
8 SARS-CoV-2 and SARS-CoV<sup>2</sup> and recent studies also pointed to the important role of ACE2 in  
9 mediating entry of SARS-CoV-2<sup>2, 3</sup>.

10  
11 Currently, there is no specific treatment for COVID-19 and therapeutic options in response to the  
12 COVID-19 outbreak are urgently needed<sup>4, 5</sup>. For above reasons, there are several options can be  
13 considered for drug discovery: the first one is to screen anti-viral drugs that are approved by  
14 government agency with good safety profiles. The second one is to keep a close watch on virus  
15 entry and replication in the target cells. From this point of view, clinical trials are under way to test  
16 the safety and efficacy of recombinant human ACE2 in the treatment of COVID-19<sup>6</sup>. As early as  
17 February 2020, a Chinese research team discovered that remdesivir and chloroquine could  
18 effectively inhibit the SARS-CoV-2 in vitro by screening of the antiviral efficiency of five  
19 FDA-approved drugs<sup>7</sup>. In line with this regard, currently, at least 80 trials related to the chloroquine,  
20 hydroxychloroquine have been registered worldwide<sup>8</sup>. On the other hand, nearly twenty clinical  
21 trials regarding the remdesivir were also registered worldwide. In addition, by compassionate-use  
22 of remdesivir, clinical improvement was observed<sup>9</sup>. While we still need to accelerate and fine-tuning  
23 drug development to control infection rate, improve cure rate and decrease mortality of COVID-19.

24  
25 LL- 37 is against a variety of viruses<sup>10</sup>, including the human acquired immunodeficiency virus  
26 (HIV-1)<sup>11</sup>, influenza a virus (IAV)<sup>12</sup>, respiratory syncytial virus (RSV)<sup>13</sup>, rhinovirus<sup>14</sup>, herpes simplex  
27 virus (HSV)<sup>15</sup> Zika virus<sup>10</sup> and hepatitis c virus (HCV)<sup>16</sup>, etc., mainly through the interaction with cell  
28 membrane and virus shell to play antiviral effects. When the antimicrobial form binds to the cell  
29 membrane, the antimicrobial form disrupts the lipid layer, increasing the permeability of the cell  
30 membrane and leading to the outflow of material from the cell, thus killing the microorganism<sup>17</sup>.  
31 Antibacterial peptide LL-37 can induce antigen-presenting cells to produce a strong immune  
32 response, by producing and releasing type I interferon and promoting the maturation of dendritic  
33 cells, enhancing the transmission of viral dsDNA to toll-like receptors located near the nucleus, thus  
34 achieving an effective antiviral effect. There is a clinical study demonstrating that treatment with  
35 LL-37 for chronic leg ulcers was safe and well tolerated with the marked effect on healing  
36 predictors<sup>18</sup>.

37  
38 *Lactococcus lactis* is non-pathogenic, non-colonizing bacterium and is one of the most commonly  
39 used microorganisms in the dairy industry and has an excellent safety record. Genetically modified  
40 probiotic *Lactococcus lactis* can serve as vectors for local delivery of biologically active molecules<sup>19</sup>.  
41 Several clinical studies were conducted with *Lactococcus lactis*, either bacteria itself on chronic  
42 rhino sinusitis (NCT04048174) and pre-hypertensive subjects (NCT02670811) or genetically  
43 modified *Lactococcus lactis* that has been engineered to secrete human Interleukin-10 (hIL-10)  
44 which is now in a phase I trial to treat Crohn's disease<sup>20</sup>, a Phase II study in Ulcerative Colitis  
45 (NCT00729872) or used as malaria vaccine hybrid GMZ2 (NCT00424944); What's more,  
46 *Lactococcus lactis* secreting human TFF1 (Trefoil Factor 1) is in a phase II, double-blind,  
47 placebo-controlled, 2-arm, multi-center trial (NCT03234465). These studies all indicated that  
48 *Lactococcus lactis* displays an excellent safety profiles.

1 The purpose of this study was to determine the safety and efficacy of the cas001 in the treatment of  
2 patients with COVID-19.

### 3 4 **Materials and animals**

5 The food grade bacterial strains *Lactococcus lactis cremoris*, NZ3900 (Cat# VS-ELS03900-01) and  
6 plasmids pNZ8149 (Cat# VS-ELV00300-01) & pNZ8148(Cat# VS-ELV00200-01) were purchased  
7 from MoBiTec GmbH, Germany. In addition, fermenting materials were supported by Beijing  
8 Aoboxing Bio-Tech Co., LTD. Human LL-37 peptides came from GenScript Biotech Corporation  
9 (Cat# RP13323). Other biomedical reagents came from the Sigma-Aldrich company.

10 7-week-old male C57BL/6J mice and SD Rats were purchased from Vital River Laboratory Animal  
11 Technology. Co. LTD. Each mouse (n=5) was treated by 1.0E9 frozen-dried powder of  
12 chloromycetin resistant recombinant bacteria once and feces were collected for counting viable  
13 bacteria by pour plate method at 3, 9, 15, 27, 39 and 51 hr after administration respectively. After a  
14 week of adjustable feeding, male (n=10) and female (n=10) SD Rats were randomly separated into  
15 equal-number-individual groups respectively according to body weight and treated with  
16 6.0E10/kg-day frozen-dried powder by gavage in the animal safety assessment. In the following  
17 two weeks, body weight, water drink, food intake, blood routine examination, serum biochemical  
18 analysis and daily observation were recorded to assess the risk of drug. For pharmacokinetics  
19 tracking, rats of same age were treated with same dose of recombinant bacteria (n=3), blood  
20 samples were collected from tail tip at 0, 1, 2, 4, 6 hr after gavage. Serum LL-37 concentration were  
21 detected by Hycult biotechnology human ELISA KIT (Cat# HK321).

### 22 23 **Ethics**

24 Animals were housed under a 12/12 hr light/dark cycle with free access to food and water. Before  
25 sacrifice, animals were given an anesthetic and cervical dislocation rapidly to relieve pain. All  
26 animal studies were approved by the Institutional Animal Care and Use Committee of Institute of  
27 Zoology, Chinese Academy of Sciences.

28  
29 The clinical human study was approved by the Ethics committee of Chinese PLA General Hospital  
30 (S2020-074-04) and all participants signed an informed consent according to the requirement of  
31 the Ethics committee. Based on safety concerns, the ethics committee requested a small  
32 exploratory clinical trial in which participants are patients with mild symptoms of COVID-19, and the  
33 study mainly focused on assessing the clinical safety prior to large-scale clinical study. At the same  
34 time, this study was registered on the west China website. (<http://www.chictr.org.cn>,  
35 ChiCTR2000030939).

### 36 37 **Plasmid cloning and transformation**

38 The construction of DNA element is shown in the Figure 1B, DNA sequence was submitted to  
39 GenScript Biotech Corporation for gene synthesis and sub-cloning into pNZ8149. The  
40 pNZ8149-7xLL-37 recombinant vector were transferred into home-made NZ3900 competent cell  
41 through Gene PulserXcell™ electroporation system (BioRad, California, USA) to produce cas001.

### 42 43 **Cell culture**

44 The cas001 were cultured at 30°C up to 9-10 hours in mixed M17 media (0.5% Soya peptone, 0.25%  
45 peptone, 0.25% Casein peptone, 0.25% Yeast Extract, 0.5% Beef Extract, 0.05% Ascorbic acid, 1.9%  
46 β-Disodium Glycerophosphate and 0.025% MgSO4·7H2O, adjusted to pH 7.2, replenishing 0.5%  
47 Lactose after being autoclaved before use) until the end of logarithmic growth phase. Before  
48 vacuum freeze-drying, these probiotics were collected by centrifuging and mixed with  
49 cryoprotectant (3.5% skim milk powder, 19.5% maltodextrin) in the right proportions for oral

1 administration. Vero cell line, the courtesy of Aihua-Zheng, Ph.D, were cultured in DMEM high  
2 medium with 8%FBS, at 37 °C and 5% CO<sub>2</sub>.

### 3 4 **Gene expression and western blotting**

5 The cas001 were taken out from ultra-low temperature refrigerator for overnight activation twice at  
6 30 °C in M17 medium. Then the pure culture above was transferred into 10 ml fresh M17 medium  
7 for stationary culture until OD600 was around 0.4-0.6, different concentrations of nisin was added  
8 to induce the LL-37 fusion protein expression. Finally proteins in supernatant were concentrated by  
9 acidulated organic solvent precipitation for western blotting detection of target protein. The specific  
10 human LL-37 primary antibody came from Santa Cruz Biotech, CA, USA (Cat# sc-166770).

### 11 12 **Anti-virus infection experiment in vitro**

13 GFP labeled-recombinant vesicular stomatitis virus-SARS (rVSV-SARS) and vesicular stomatitis  
14 virus-SARS-CoV2 (rVSV-SARS-CoV2) were gifts from Aihua-Zheng, Ph.D. The surface  
15 G-attachment glycoprotein of rVSV was specifically replaced by the spike protein of SARS or  
16 SARS-CoV2. The rVSV-SARS or rVSV-SARS-CoV2 were diluted into 2000 ffu/ml as working  
17 solution, then different doses of LL-37 were added into working solution respectively and incubated  
18 for 30 min at room temperature. Then vero cells copped in 96 well plate were changed the medium  
19 with this working solution and continued to culture for 2 hr at 37 °C, each group was performed with  
20 three biological replicates. Afterwards vero cells were replaced with fresh medium including 20 mM  
21 NH<sub>4</sub>Cl to terminate virus infection for 14 hr at 28 °C. Finally the GFP positive colony numbers were  
22 recorded by manual counting to calculate the inhibition rate.

### 23 24 **Histology**

25 All organs fixed in 10% formalin solution were embedded with paraffin and sectioned. Multiple  
26 sections defining the embedding direction and observation position in different organs were  
27 prepared for haematoxylin and eosin staining. The images were accessed by an Olympus BX51  
28 system.

### 29 30 **Patients**

31 The research ethics committee of Chinese PLA General Hospital (S2020-074-04) approved the  
32 study and all participants signed an informed consent according to the requirement of Ethics  
33 Commission. The studied subjects were from wuhan hankou hospital and huoshenshan hospital.  
34 All the patients were mild inpatients who were positive for nucleic acid test when enrolled. They met  
35 the inclusion requirements of the ethics committee. All subjects signed the informed consent. Since  
36 the patients had received systemic treatment in the local hospital at enrollment, for the sake of  
37 safety, on the premise that the original treatment plan was unchanged, the subjects were given  
38 extra LL-37 treatment by oral administration for 3 pills, 1 time/8 hours, and for 3 weeks. Baseline  
39 clinical information was collected, including demographic characteristic, clinical symptoms, blood  
40 test results, nucleic acid test results, lung CT results, etc., and follow-up was conducted once a  
41 week to evaluate the improvement of patients' clinical symptoms and adverse reactions.

### 42 43 **Statistical Analysis**

44 All data were shown by Mean ± SEM. Comparisons between groups were made with one-way  
45 ANOVA with Tukey's post-hoc test or Student's t-test. Repeated measurement analysis was made  
46 by both factors RM two-way ANOVA. p value < 0.05 was regarded as statistically significant.

### 47 48 **Results**

#### 49 **The recombinant pNZ8149-7xLL-37 construction and gene expression**

---

1 As a food grade bacterial strains, lactococcus lactis was usually regarded as a very convenient  
2 living oral drug carrier which could transport protein drugs or vaccines. Here we designed a  
3 recombinant lactococcus lactis carrying LL-37(cas001), a human endogenous antiviral peptide to  
4 treat COVID-19 (Fig. 1A). In order to express the shorter target polypeptide, we combined signal  
5 peptide, LEISS enhancing sequence with seven tandem repeated sequences encoding mature  
6 human LL-37 under control of the nisin-inducible nisA promoter (Fig. 1B-C). The cas001 could  
7 secrete target protein (~34KD) into supernatant followed by addition of inducer Nisin(Fig. 1D).  
8 Therefore we successfully constructed LL-37 over-expressing lactococcus lactis.

### 9 10 **LL-37 impaired rVSV-SARS and rVSV-SARS-CoV2 infection in vitro**

11 We investigated the inhibitory effect of LL-37 on virus entry into the target cells with the simulated  
12 viruses of SARS and SARS-CoV2 as follows. S protein is the main immunogen of coronavirus  
13 mediating virus infection. The rVSV-SARS and rVSV-SARS-CoV2 recombinant viruses were  
14 constructed by replacing the G protein of VSV with the S protein of SARS and SARS-CoV2, and the  
15 S protein was displayed on the surface of the VSV virus, respectively. The recombinant virus can  
16 simulate the infection process of SARS and SARS-CoV2.

17  
18 To verify LL-37 effect in inhibiting SARS virus, packaged rVSV-SARS virus was diluted to 2000  
19 ffu/ml as virus solution. LL-37 was then diluted to 0 ng/ml, 10 ng/ml, 100 ng/ml, 1000 ng/ml, 10000  
20 ng/ml, 100000 ng/ml using virus solution to get different concentrations of treatment solution. After  
21 incubation for 30 minutes at the room temperature, different concentrations of treatment solution  
22 were used to treat vero cells in 96-well plates, with 100ul per well and 3 multiple wells for each  
23 concentration. The cells were placed in a 37°C cell incubator. The fresh medium containing 20 mM  
24 NH<sub>4</sub>Cl was added in place of treatment solution 2 hours after virus infection, and the cells were  
25 placed in cell incubator at 28°C. The number of cells with positive fluorescence signal was counted  
26 under fluorescence microscope 24 hours after infection. Finally, according to the comparison test  
27 results, the antiviral ability of LL-37 was identified. The maximum inhibition rate of LL-37 was 85%  
28 at the concentration of 10ug/ml (Fig. 2A). The ability of LL-37 to inhibit SARS-CoV2 infection was  
29 measured in similar manner. At a concentration of 100ng/ml, LL-37 inhibited the ability of  
30 SARS-CoV2 to invade Vero cells by 41.5% (Fig. 2B).

### 31 32 **Results of the subchronic toxicity experiment showed that cas001 displayed good safety profiles**

33  
34 The acute and subchronic toxicity test of LL-37 was performed in rats to evaluate its safety. We  
35 produced special Lactococcus Lactis with chloramphenicol resistance. Using culture plates with  
36 chloramphenicol resistance, we detected specially-made probiotic bacteria number in feces to  
37 determine its colonization in the gut. The chloramphenicol-resistant bacteria were administrated to  
38 mice by gavage ( $1 \times 10^9$  CFU/mice), and the feces were collected at different time after the gavage  
39 (Fig. 3A). In order to determine the blood pharmacokinetic profile of LL-37, male SD rats (body  
40 weight 250-300g,  $1 \times 10^{10}$  CFU/animal, n=3) were given oral administration of cas001. The  
41 concentration of LL-37 in the blood before and after gavage was detected using ELISA kit (Hycult  
42 biotechnology Cat# HK321). Results showed that 2 hours after gavage, the concentration of LL-37  
43 in the blood reached the peak (Fig. 3B).

44  
45 In the animal safety evaluation experiment, 100 times of the expected clinical dose of drug was  
46 given to rats by oral gavage at the dose of  $6 \times 10^{10}$  CFU//kg/ day. The results showed that LD<sub>50</sub> of  
47 LL-37 was more than  $6 \times 10^{10}$  CFU/kg/ day. Observation during 14 days of administration showed  
48 that all SD rats were generally in good condition both during and after administration and no  
49 abnormal performance was observed in SD rats (data not shown). The body weights showed no



1 significant difference between the treatment group and the control group (Fig. 3C), indicating that  
2 the oral cas001 did not affect the weight gain. During the observation period, the food intake, water  
3 intake, organs weight and histological examination results of SD rats in treatment group were not  
4 significantly different from those of the control group (Fig. 3D-G), indicating that under this  
5 experimental condition, cas001 did not affect the appetite of experimental animals. The results of  
6 blood biochemistry examination indicated that there was no significant difference in liver, kidney  
7 function, myocardial enzyme concentration, blood lipid concentration and electrolyte concentration  
8 between the two groups of SD rats (all p values were > 0.05) (Table. 1) .  
9

10 To assess pharmacokinetics in human individuals, four healthy adult volunteers were recruited to  
11 the study (Table. 2). During dose escalation study periods, the volunteers did not feel any  
12 discomfort while taking the cas001 capsules, such as fatigue, weakness, nausea, vomiting, etc.  
13 Two hours after oral administration, the concentration of LL-37 level was increased in healthy  
14 volunteers (#1 volunteer who took highest dose of cas001, increased significantly, the others only  
15 increased slightly) (Table. 3). Accordingly, there was no significant change in liver and kidney  
16 function after oral cas001 medication (Table. 4). All these results taken together, cas001 displays  
17 an excellent safety profile in both preclinical trials and healthy volunteers assay.  
18

### 19 **Cas001 significantly improved symptoms of COVID-19 patients**

20 With the approval of ethics committee of Chinese PLA General Hospital (Ethics no. : s2020-074-04),  
21 the investigator-initiated clinical trial (ITT) was carried out, which mainly focused on safety  
22 assessment and small-scale, single-arm, exploratory safety study was performed. A total of 11  
23 eligible patients with mild symptoms were enrolled in Wuhan Hankou hospital and Huoshenshan  
24 hospital. They were enrolled voluntarily and all patients signed informed consent. Among them,  
25 there were 5 males and 6 females, aged  $55 \pm 12$  (36-70) years old, and the duration from onset to  
26 medication enrollment was  $35 \pm 19$  (5-68) days. 6 patients were nucleic acid positive and 5 patients  
27 were nucleic acid negative when they were enrolled. All patients received the cas001 treatment  
28 according to requirement (3 capsules/time, three times a day for 3 weeks), with an average  
29 follow-up time of  $33 \pm 15$  days (Table. 5).

30 At the time of enrollment, the patients' symptoms included three categories, among which the  
31 positive systemic symptoms mainly included fever, fatigue and myalgia. After treatment, the  
32 improvement rate of systemic symptoms was 100%, and the time from medication to the complete  
33 remission ranged from 5 to 33 days; Respiratory symptoms included pharyngalgia, cough, chest  
34 distress, shortness of breath, which were improved completely 7-14 days after treatment with  
35 improvement rate up to 100%; Gastrointestinal symptoms including abdominal discomfort, nausea,  
36 poor appetite, and diarrhea were completely improved within 2-18 days after treatment. Among all  
37 symptoms, gastrointestinal symptoms were improved fastest with the shortest improvement time of  
38 2 days (Table. 6).

39 Among the 11 patients enrolled, 5 were positive for nucleic acid test before medication, 6 were  
40 negative. After treatment, 4 of the 5 positive patients were negative for nucleic acid test. The  
41 duration from taking the medicine to recovery was 19, 17, 9 and 17 days respectively. All patients  
42 received lung CT examination before the enrollment and nine of them showed abnormal lung CT  
43 results. During the follow-up period, a total of 4 cases completed the reexamination of lung CT, 3  
44 cases of them have been completely improved, the duration from medication to complete  
45 improvement was 44, 48, 50 days, respectively; Another 1 case improved 75%, costing 17 days  
46 from medication to improvement. The remaining 5 patients did not complete the pulmonary CT  
47 reexamination due to home isolation/quarantine place isolation after discharge (Table. 7).

48 11 patients enrolled showed good compliance, tolerance, subjective feeling and actively interacted  
49 with the doctors. None of the patients had any adverse reactions, and the observation of adverse

1 reactions was performed with reference to literatures<sup>21</sup>. Living bacteria drugs may cause four types  
2 of adverse reactions theoretically, including gastrointestinal related adverse reactions, infection,  
3 harmful metabolic effects, excessive immune stimulation of susceptible individuals and gene  
4 transfer<sup>22</sup>. There was no clinical evidence for the occurrence of the latter two, and the main  
5 manifestations of the other three types of adverse reactions including infection<sup>23-29</sup>, harmful  
6 metabolic effect<sup>30</sup>, gastrointestinal related adverse reactions<sup>22</sup> were as follows (Table. 8). During  
7 the observation of this clinical study, none of the patients presented adverse reactions shown in  
8 table 4 or any other ones.

## 9 10 **Discussion**

11  
12 There is a report indicating that although gastrointestinal symptoms were uncommon, still a part of  
13 patients showed gastrointestinal symptoms, such as diarrhea (3.8%) and vomiting (5.0%)<sup>31</sup>. In line  
14 with this observation, there are numbers of studies demonstrating that SARS-CoV-2 can be  
15 detected in the gastrointestinal tract<sup>32, 33</sup>. Since the SARS-CoV-2 spike glycoprotein binding to  
16 ACE2 receptor is a critical step for virus entry, investigation of the expression pattern of ACE2 in  
17 host specific target cells or organs is particular important. Accordingly, a report demonstrated that  
18 ACE2 is rarely expressed in esophageal epithelium but is abundantly distributed in the cilia of the  
19 glandular epithelia<sup>33</sup>. These results imply that we cannot exclude the possibility of fecal-oral  
20 transmission.<sup>34</sup>

21  
22 Lactococcus lactis could be used to treat GIT related diseases such as colitis and inflammatory  
23 bowel disease (IBD) due to its survival ability in gastrointestinal tract (GIT) and its  
24 immunomodulatory properties. In fact, engineered Lactococcus lactis secreting interleukin-10  
25 (IL-10) was used to treat murine colitis<sup>19</sup>. Although clinical outcome was not as promising as hoped  
26 in human crohn's disease<sup>20</sup>, similar clinical trials addressed concerns related to release of  
27 lactococcus lactis. It should be noted that we should consider the properties of lactococcus lactis in  
28 the mucosal immunity, besides systemic target protein secretion by GMOs. Interestingly, a report  
29 demonstrated that lactococcus lactis induced mucosal IgA which can form a barrier to pathogens  
30 on the mucosal surface<sup>35</sup>. Whether cas001 could also induce IgA mucosal immunity needs further  
31 investigation.

32  
33 According to the scope of study and number of cases approved by the medical ethics committee,  
34 the first phase of the single-arm, symptomatically oriented investigator initiated clinical trials (ITT)  
35 which enrolled 11 patients have been successfully completed. From the results of research and  
36 follow-up, patients were well tolerated, characterized by good compliance and feeling after taking  
37 cas001. The adverse reactions reported in the symptomatology and probiotics related literatures  
38 include: gastrointestinal related adverse reactions, infection, and harmful metabolic effects, while  
39 all of the above were not observed in the study. Therefore, from this small scale exploratory  
40 research, the good safety of cas001 was preliminarily verified.

41  
42 All patients enrolled are mild in symptoms and in convalescence, the ratio of male : female is  
43 appropriate, the duration from the onset to the enrollment is at the average of 34 days. After the  
44 medication, systemic symptoms, respiratory symptoms, gastrointestinal symptoms were improved  
45 to varying degrees, among them gastrointestinal symptoms were improved significantly. The  
46 improvement rate of respiratory symptoms was 100%, all patients showed improvement during the  
47 follow-up period, and no recurrence of the above symptoms occurred during the follow-up period  
48 after drug withdrawal. There were 5 patients with positive nucleic acid test results at the beginning  
49 of medication, and 4 patients turned negative after an average of 15 days medication. Another

1 patient was in home isolation and did not receive reexamination. Whether the change of the nucleic  
2 acid test results is related to cas001 is not easy to infer at present. In terms of the improvement of  
3 lung CT results, 3 cases got completely improved and 1 case got 75% improved. It took 7days for  
4 recovery from mild inflammation to complete absorption of inflammation. Whether the cas001  
5 improves or accelerates healing process remains to be investigated. Overall, cas001 shows  
6 definite effect in the improvement of gastrointestinal symptoms and is possible to have effects in  
7 improving the systemic symptoms and respiratory symptoms and may play a role in the  
8 improvement of results of nucleic acid test and lung CT test.

9  
10 This study is limited to a small scope and mainly focuses on the safety exploration. The epidemic of  
11 novel coronavirus in China is in the clearance phase, so the number of medical records included  
12 from the above two centers is very limited. What's more, there are few clinical cases related to  
13 cas001, which is a major defect of current clinical study. In addition, all patients were discharged  
14 from the hospital 3-5 days after enrollment, and were isolated at home or in a quarantine place,  
15 resulting in incomplete blood and CT follow-up data. The follow-up time is relatively short, and  
16 further evaluation is needed to see whether there are new safety problems in the middle phase (3-6  
17 months) and the adverse reactions in middle and later phase. While, since *Lactococcus lactis* is not  
18 colonized in the body and has a short metabolic cycle and did not cause any adverse effects in  
19 short term observation, there is little possibility that cas001 would cause adverse reactions in  
20 middle and later phase.

21  
22 This small scale exploratory study suggested that the oral cas001 has good clinical tolerance and  
23 significant safety. Cas001 has positive effect in the improvement of symptoms and nucleic acid  
24 clearance in patients with mild symptoms, especially in the improvement of gastrointestinal  
25 symptoms, suggesting that this drug could be used to treat patients with mild symptoms as an  
26 auxiliary drug or as a single cure for clinical application. Its efficacy and safety still need to be  
27 further confirmed by prospective, large sample, multi-center, randomized, double-blind, controlled  
28 studies and long-term follow-up.

### 29 30 **Limitations**

31 Current study has several following limitations. Firstly, primary purpose of current clinical trial is  
32 assessment of safety profiles. In this regard, we did not performed dose escalation study, therefore,  
33 optimal clinical dose of cas001 is not yet fully determined. Secondly, this was a small scale single  
34 arm clinical trial without control. It is hard to reach conclusion of clinical outcomes related to the  
35 cas001, although changes of several symptoms indicating encouraging findings. Thirdly, before  
36 taking cas001, these self-quarantined patients with mild symptoms had received other antiviral  
37 drugs. It is unclear if these patients would be improved without cas001 treatment. Fourthly, it is hard  
38 to measure circulating LL-37 in patients due to viral contamination. Finally, we also could not  
39 directly quantify viral load because of limited number of patients available in the study and most of  
40 them were with mild symptoms and nucleic acid positive and were self-quarantined.

### 41 42 **Conclusions**

43 In current preliminary uncontrolled study enrolling 11 patients with COVID-19, administration of  
44 cas001 has promising clinical outcomes. The small sample size and uncontrolled study design  
45 preclude a definitive statement about the potential effectiveness of cas001, and further evaluation  
46 in large-scale clinical trials is required.

### 47 48 **Acknowledgement**

49 This work was supported by the National Key Research and Development Program of China

(2017YFC1001001), the National Natural Science Foundation of China (81770834), the Youth Program of National Natural Science Foundation of China (31900830) from the Chinese Academy of Sciences and the China Postdoctoral Science Foundation Funded Project (2018M640182). We would also like to thank Professor Cheng Wang from Harvard University for his great support for this study.

## Author contribution

H. Zhang, X. Jiang, C. Yan, J. Jiao, C. Zhao and H. Li together carried out the experiments. H. Zhang, Y. Zhao, X. Jiang, Li Chen and M. Dong together wrote the manuscript. Y. Zhao, Z. Luan, W. Chen, C. Feng, L. Tian, E. Qin, J. Mu, C. Li collected the clinical data and made revisit. T. Zeng, S. Feng, S. Wang, X. Guan, T. Li and H. Yu contacted hospitals and patients and analyzed the results. A. Zheng, W. Jin, G. Sun conceived the project. All authors were involved in editing the paper and had final approval of the submitted and published versions.

## Conflicts of Interest

The authors declare no conflict of interest.

---

## Legend

### Figure 1. Design principles of oral antiviral drugs and recombinant vector construction

(A) Principle of oral administration of living biological drugs. (B) Amino acid sequence of recombinant 7xLL-37. (C) Agarose gel electrophoresis results of PCR fragments and suspected positive clone. (D) Western blotting detection of induced gene expression of recombinant vector in vitro.

### Figure 2. LL-37 impaired rVSV-SARS and rVSV-SARS-CoV2 infection in vitro

(A) Inhibition rate of LL-37 peptide on rVSV-SARS compared with vehicle(n=3). (B) Inhibition rate of LL-37 peptide on rVSV-SARS-CoV2 compared with vehicle(n=3). Multiple comparisons which were significant were represented with alphabetic notation, abc recorded as p value < 0.05.

### Figure 3. Oral administration of living biological drugs had little effect on the health of rats

(A) The bacterial counts of faeces at different time point after a single dose of oral administration of 1.0E9 frozen-dried powder with chloromycetin resistant probiotics. (B) The LL-37 concentration in rats' venous blood after a single oral administration of 3.0E10 frozen-dried powder (n=3). (C) The body weight change, (D)water intake, (E) food intake, (F) organs weight (Vehicle♂ v.s. LL-37♂, n=5; Vehicle♀ v.s. LL-37♀, n=5) were monitored during subchronic toxicity experiment. (G) H&E staining of several organs sections from rats. Scale bars in images of heart, liver, spleen, lung and kidney refer to 200 µm and those in images of whole brain refer to 2000 µm.

### Table 1. Serum biochemical detection in rats two weeks after gavage

Serum biochemistry detection of rats at the end of two weeks (Vehicle♂ v.s. LL-37♂, n=5; Vehicle♀ v.s. LL-37♀, n=5). \*represent p value<0.05.

### Table 2. Demographic information of volunteers

### Table 3. The changes of serum LL-37 concentration before and after cas001 medication

### Table 4. Serum biochemical detection of volunteers

### Table 5. Baseline patient characteristics

### Table 6. Outcomes in the intention-to-treat population

### Table 7. Nucleic acid detection and lung CT examination

### Table 8. Summary of probiotic-related adverse reactions

## References

1. Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. *Lancet* 2020; **395**(10229): 1015-8.
2. Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature* 2020.
3. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020.
4. Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. *Science* 2020; **367**(6485): 1412-3.
5. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *Jama* 2020.
6. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *The New England journal of medicine* 2020.
7. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell research* 2020; **30**(3): 269-71.
8. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. *Bmj* 2020; **369**: m1432.
9. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *The New England journal of medicine* 2020.
10. Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ. Antimicrobial host defence peptides: functions and clinical potential. *Nature reviews Drug discovery* 2020.
11. Honda JR, Connick E, MaWhinney S, Chan ED, Flores SC. Plasma LL-37 correlates with vitamin D and is reduced in human immunodeficiency virus-1 infected individuals not receiving antiretroviral therapy. *Journal of medical microbiology* 2014; **63**(Pt 7): 997-1003.
12. LeMessurier KS, Lin Y, McCullers JA, Samarasinghe AE. Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice. *Antiviral research* 2016; **133**: 208-17.
13. Harcourt JL, McDonald M, Svoboda P, Pohl J, Tatti K, Haynes LM. Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells. *BMC research notes* 2016; **9**: 11.
14. Sousa FH, Casanova V, Findlay F, et al. Cathelicidins display conserved direct antiviral activity towards rhinovirus. *Peptides* 2017; **95**: 76-83.
15. Ogawa Y, Kawamura T, Matsuzawa T, et al. Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. *Cell host & microbe* 2013; **13**(1): 77-86.
16. Matsumura T, Sugiyama N, Murayama A, et al. Antimicrobial peptide LL-37 attenuates infection of hepatitis C virus. *Hepatology research : the official journal of the Japan Society of Hepatology* 2016; **46**(9): 924-32.
17. Zeth K, Sancho-Vaello E. The Human Antimicrobial Peptides Dermcidin and LL-37 Show Novel Distinct Pathways in Membrane Interactions. *Frontiers in chemistry* 2017; **5**: 86.
18. Gronberg A, Mahlapuu M, Stahle M, Whately-Smith C, Rollman O. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. *Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society* 2014; **22**(5): 613-21.
19. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by *Lactococcus lactis* secreting interleukin-10. *Science* 2000; **289**(5483): 1352-5.
20. Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. *Clinical gastroenterology and hepatology : the official clinical*

- 1 *practice journal of the American Gastroenterological Association* 2006; **4**(6): 754-9.
- 2 21. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management.
- 3 *Lancet* 2000; **356**(9237): 1255-9.
- 4 22. Doron S, Snyderman DR. Risk and safety of probiotics. *Clinical infectious diseases : an official*
- 5 *publication of the Infectious Diseases Society of America* 2015; **60 Suppl 2**: S129-34.
- 6 23. Presterl E, Kneifel W, Mayer HK, Zehetgruber M, Makristathis A, Graninger W. Endocarditis by
- 7 *Lactobacillus rhamnosus* due to yogurt ingestion? *Scandinavian journal of infectious diseases* 2001;
- 8 **33**(9): 710-4.
- 9 24. Niault M, Thomas F, Prost J, Ansari FH, Kalfon P. Fungemia due to *Saccharomyces* species in
- 10 a patient treated with enteral *Saccharomyces boulardii*. *Clinical infectious diseases : an official*
- 11 *publication of the Infectious Diseases Society of America* 1999; **28**(4): 930.
- 12 25. Bassetti S, Frei R, Zimmerli W. Fungemia with *Saccharomyces cerevisiae* after treatment with
- 13 *Saccharomyces boulardii*. *The American journal of medicine* 1998; **105**(1): 71-2.
- 14 26. Ledoux D, Labombardi VJ, Karter D. *Lactobacillus acidophilus* bacteraemia after use of a
- 15 probiotic in a patient with AIDS and Hodgkin's disease. *International journal of STD & AIDS* 2006;
- 16 **17**(4): 280-2.
- 17 27. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. *Lactobacillus* bacteremia associated with
- 18 probiotic use in a pediatric patient with ulcerative colitis. *Journal of clinical gastroenterology* 2013;
- 19 **47**(5): 437-9.
- 20 28. Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM. *Lactobacillus* endocarditis caused by a
- 21 probiotic organism. *Clinical microbiology and infection : the official publication of the European*
- 22 *Society of Clinical Microbiology and Infectious Diseases* 1999; **5**(5): 290-2.
- 23 29. Munoz P, Bouza E, Cuenca-Estrella M, et al. *Saccharomyces cerevisiae* fungemia: an
- 24 emerging infectious disease. *Clinical infectious diseases : an official publication of the Infectious*
- 25 *Diseases Society of America* 2005; **40**(11): 1625-34.
- 26 30. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe
- 27 acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; **371**(9613):
- 28 651-9.
- 29 31. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *The*
- 30 *New England journal of medicine* 2020.
- 31 32. Wong SH, Lui RN, Sung JJ. Covid-19 and the Digestive System. *Journal of gastroenterology*
- 32 *and hepatology* 2020.
- 33 33. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of
- 34 SARS-CoV-2. *Gastroenterology* 2020.
- 35 34. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral
- 36 Transmission. *Gastroenterology* 2020.
- 37 35. Quigley BR, Hatkoff M, Thanassi DG, Ouattara M, Eichenbaum Z, Scott JR. A foreign protein
- 38 incorporated on the Tip of T3 pili in *Lactococcus lactis* elicits systemic and mucosal immunity.
- 39 *Infection and immunity* 2010; **78**(3): 1294-303.
-








Figure 1

A



B











Figure 2





**Figure 3**

Table 1. Serum biochemical detection in rats at two weeks after oral gavage of cas001

Group	TB ( $\mu$ M)	DB ( $\mu$ M)	TG (mM)	TC (mM)	AST (U/L)	ALT (U/L)	ALP (U/L)	Cr ( $\mu$ M)	BUN (mM)	LDH (U/L)	CK (U/L)	Cl (mM)	K (mM)	Na (mM)	Ca (mM)	Mg (mM)	P (mM)
Vehicle $\sigma$	0.96 $\pm$ 0.12	0.78 $\pm$ .09	0.37 $\pm$ 09	1.07 $\pm$ 08	126.74 $\pm$ 6.83	59.56 $\pm$ 3.28	160.50 $\pm$ 5.01	22.70 $\pm$ 0.68	4.00 $\pm$ 32	440.40 $\pm$ 50.26	561.62 $\pm$ 34.74	102.24 $\pm$ 0.84	6.02 $\pm$ 18	145.04 $\pm$ 0.61	2.53 $\pm$ 03	1.13 $\pm$ 03	2.86 $\pm$ 14
LL-37 $\sigma$	1.3 $\pm$ 1	1.18 $\pm$ .07*	0.29 $\pm$ 03	1.37 $\pm$ 08*	127.38 $\pm$ 10.55	47.20 $\pm$ 3.83*	152.62 $\pm$ 22.32	22.38 $\pm$ 0.48	4.65 $\pm$ 33	571.86 $\pm$ 71.69	661.02 $\pm$ 93.22	101.24 $\pm$ 0.29	5.68 $\pm$ 15	145.06 $\pm$ 0.36	2.54 $\pm$ 01	1.04 $\pm$ 04	2.81 $\pm$ 07
Vehicle $\text{f}$	1.2 $\pm$ 3	1.10 $\pm$ .22	0.32 $\pm$ 03	1.47 $\pm$ 25	152.30 $\pm$ 14.58	39.98 $\pm$ 2.11	72.06 $\pm$ 4.78	25.60 $\pm$ 2.82	4.85 $\pm$ 34	833.46 $\pm$ 371.28	954.30 $\pm$ 394.79	102.30 $\pm$ 0.91	5.20 $\pm$ 42	143.26 $\pm$ 0.82	2.50 $\pm$ 08	1.02 $\pm$ 04	2.63 $\pm$ 14
LL-37 $\text{f}$	1.36 $\pm$ 0.19	1.18 $\pm$ .22	0.33 $\pm$ 07	1.30 $\pm$ 20	103.78 $\pm$ 10.00*	39.48 $\pm$ 1.14	64.60 $\pm$ 4.60	27.76 $\pm$ 1.26	5.02 $\pm$ 23	349.50 $\pm$ 142.26	715.56 $\pm$ 343.35	102.42 $\pm$ 0.82	5.13 $\pm$ 11	143.58 $\pm$ 0.42	2.62 $\pm$ 03	1.00 $\pm$ 02	2.53 $\pm$ 12

\*represent p value < 0.05.

Table 2. Demographic information of volunteers

No.	Gender	Age(year)	Body Weight(kg)	Height(m)	BMI(kg/m <sup>2</sup> )	Doses of probiotic(/human)
1	Male	45	75	1.75	24.5	1.0E10
2	Female	40	54	1.67	19.4	3.0E9
3	Male	31	68	1.76	22.0	6.0E9
4	Female	31	54	1.60	21.1	3.0E9

Table 3. The changes of serum LL-37 concentration before and after cas001 medication

LL-37 (ng/ml)	Time (0h)	Time (2h)
Male1	54.1	65.7
Female2	34.1	35.2
Male2	39.4	42.3
Female4	38.3	41.2

Table 4. Serum biochemical detection of volunteers

Index	Treatment	Before				After 2 hr			
	Standard values	Male1	Female1	Male2	Female2	Male1	Female1	Male2	Female2
ALT (U/L)	0-40	12.6	7.8	22.4	6.6	10.2	7.1	25.1	3.8
TP (g/L)	55-80	77	77.6	72.3	73.6	76.2	76.7	73.2	74.1
TB (μmol/L)	0-21	9	3.4	5.3	3.3	9.1	4.1	6	3.4
Tn (ng/ml)	0-0.1	<0.0030	<0.0030	0.011	<0.0030	<0.0030	<0.0030	0.011	<0.0030
γ-GT(U/L)	0-50	12.1	10.9	25.1	10.8	12.7	10.3	26	11.8
Cr (μmol/L)	30-110	90.2	58.8	83.2	77.1	88.3	53.6	82.5	69.4
Ca (mmol/L)	2.09-2.54	2.41	2.47	2.4	2.42	2.44	2.54	2.43	2.47
Mg (mmol/L)	0.6-1.4	0.95	0.9	0.85	0.79	0.91	0.85	0.81	0.79
Na (mmol/L)	130-150	140.3	137.6	140.4	140.1	139	136.4	140.2	139.5
CO2 (mmol/L)	20.2-30.0	25.5	23.4	22	21.8	26.1	22.6	24.2	22.8
LPS (U/L)	13-60	27.1	44.4	53.1	26.4	28.4	40.3	49.1	26.6
CK-MB (ng/ml)	0-6.5	1.67	1.32	2.1	1.48	1.65	1.03	1.71	1.04
AST (U/L)	0-40	19	15.2	25.7	15.4	15.8	15.2	25	13.6
ALB (g/L)	35-50	51.2	49.3	46.8	49.6	52.3	47.3	48.3	48.8
DB (μmol/L)	0-8.6	4.2	2.2	2.5	2	4.2	2.3	2.8	2.2
ALP (U/L)	42-396	51	36.9	40.6	50.5	50.4	35.5	37.4	53.8
BUN (mmol/L)	1.8-7.5	4.79	6.64	5.45	5.79	4.55	6.23	5.73	6.06
UA (μmol/L)	104-444	316.2	251.7	377.8	370.9	313.5	249.6	372.4	364.5
LDH (U/L)	40-250	168.8	174.5	217.2	165.6	167.6	169.3	184.9	132.3
P (mmol/L)	0.89-1.6	1.37	1.43	1.14	1.51	1.35	1.51	1.26	1.25
K (mmol/L)	3.5-5.5	3.99	4.29	3.89	4.42	3.95	4.24	4.01	4.2
Cl (mmol/L)	94-110	100.4	101	104.8	102.8	100.2	101.5	103.1	103.5
AMS (U/L)	0-150	71	59.8	69.9	65	69.7	59.3	68.4	64.7
Mb (ng/ml)	0-75	<21.0	<21.0	76.7	<21.0	<21.0	<21.0	41.7	<21.0
LDH-MB (U/L)	17-72	40	38.5	48.3	42.8	38.5	36.5	38.3	32.3

Table 5. Baseline patient characteristics

Name	Gender	Age	Time from onset to enrollment (d)	Clinical classification	Nucleic acid test at enrollment
Patient #1	F	57	5	mild	+
Patient #2	F	70	30	mild	+
Patient #3	M	70	30	mild	+
Patient #4	M	51	37	mild	+
Patient #5	M	57	35	mild	+
Patient #6	M	36	68	mild	-
Patient #7	F	42	5	mild	-
Patient #8	F	65	36	mild	+
Patient #9	M	65	33	mild	-
Patient #10	F	40	47	mild	-
Patient #11	F	57	58	mild	-

Table 6. Outcomes in the intention-to-treat population

	Systemic symptoms			Respiratory symptoms					Gastrointestinal symptoms			
Observation index	fever	weak	myalgia	pharyngalgia	cough	chest distress	dyspnea	shortness of breath	abdominal discomfort	nausea	poor appetite	diarrhea
Positive cases	2	6	4	2	5	3	1	3	7	2	3	4
Average duration of improvement (day)	4	14	16	6	17	12	7	9	10	5	14	12

Table 7. Nucleic acid detection and lung CT examination

Observation index	Positive cases at enrollment	Reexaminaion cases *	Completely recovered cases	75% recovered cases (CT)	Average medication time(d)	Negative conversion rate/complete absorption rate(%)	Partial absorption rate(%)
Nucleic acid detection	5	5	5	-	15	100	-
Lung CT	9	4	3	1	47	100	100

\* The remaining 5 patients did not complete the pulmonary CT reexamination due to home isolation/quarantine place isolation after discharge



Table 8. Summary of probiotic-related adverse reactions

Category	Detailed adverse reactions	Cases observed
Infection 【Ref 23-29】	bacteremia, fungemia, sepsis, endocarditis	0
Harmful metabolic effects 【Ref 30】	intestinal ischemia, D-lactic acid poisoning	0
Gastrointestinal related adverse reactions 【Ref 22】	diarrhea, abdominal distension, abdominal discomfort, stool shape change, nausea, vomiting	0